Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Masimo ( (MASI) ) has shared an announcement.
On May 6, 2025, Masimo Corporation announced its financial results for the first quarter of 2025, reporting a 10% increase in GAAP revenue to $372 million and a 56% rise in non-GAAP net income per diluted share compared to the previous year. The company also provided an updated outlook for fiscal 2025, anticipating non-GAAP revenue growth of 8% to 11% and addressing the impact of new tariffs with mitigation strategies, highlighting its strong market position and operational resilience.
Spark’s Take on MASI Stock
According to Spark, TipRanks’ AI Analyst, MASI is a Neutral.
Masimo’s overall stock score reflects a mixed outlook. The company exhibits strong cash flow and positive future guidance, but profitability challenges and valuation concerns weigh on the score. Technical indicators suggest neutral momentum, and strategic shifts are underway to enhance future performance.
To see Spark’s full report on MASI stock, click here.
More about Masimo
Masimo Corporation operates in the healthcare industry, focusing on the development and manufacturing of innovative noninvasive monitoring technologies. The company is known for its advanced medical devices and solutions that enhance patient care and safety.
Average Trading Volume: 596,477
Technical Sentiment Signal: Buy
Current Market Cap: $8.99B
Learn more about MASI stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue